SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said it has submitted a supplemental Biologics License Application to the ...
Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is currently the only approved treatment for CAD and is a ...
(RTTNews) - Sanofi - Aventis Groupe said that the European Commission has granted marketing authorization for Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold ...
Tranekær S, Hansen DL, Frederiksen H. Epidemiology of secondary warm autoimmune haemolytic anaemia-A systematic review and meta-analysis. J Clin Med . 2021 ...
Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia — a condition in which you have inadequate red blood cells due to premature destruction of those cells by your own immune ...
/ -- Autoimmune hemolytic anemia (AIHA) treatment encompasses a range of therapeutic strategies aimed at mitigating the immune system's attack on red blood cells, thereby alleviating anemia and ...
Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had ...
Cold agglutinin disease is a condition that causes low red blood cell (RBC) counts. Symptoms can include fatigue, weakness, or shortness of breath. Cold agglutinin disease is a type of autoimmune ...
Q. I’ve just been diagnosed with anemia. What are its causes, and how is it treated? A. Blood is made up of red blood cells that bring oxygen to the tissues of the body, white blood cells that fight ...
Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results